key: cord-0683199-pfb3l2u3
authors: Veenstra, Jesse; Buechler, Connor R.; Robinson, Gabrielle; Chapman, Stephanie; Adelman, Madeline; Tisack, Aaron; Dimitrion, Peter; Todter, Erika; Kohen, Laurie; Lim, Henry W.
title: Antecedent Immunosuppressive Therapy for Immune-Mediated Inflammatory Diseases in the Setting of a COVID-19 Outbreak
date: 2020-07-28
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2020.07.089
sha: 31d0bd1d22d802171fe1b0f3ec108052588d6e99
doc_id: 683199
cord_uid: pfb3l2u3

Abstract Background Finite clinical data and understanding of COVID-19 immunopathology has led to limited, opinion-based recommendations for management of immune-mediated inflammatory disease (IMID) patients on immunosuppressive (IS) therapeutics. Objective Determine if IS therapeutic type impacts COVID-19 risk among IMID patients. Methods We conducted a retrospective cohort analysis of Henry Ford Health System (HFHS) patients tested for COVID-19 between February 1st and April 18th, 2020 treated with IS medication for IMID. Therapeutic class of IS medication, comorbidities, and demographic factors were combined into multivariate models to determine predictors of COVID-19 infection, admission, ventilation, and mortality. Results Of 213 IMID patients, 36.2% tested positive for COVID-19, who had no greater odds of being hospitalized or requiring ventilation relative to the general population. No IS therapeutic worsened the course of disease after multivariate correction, though multi-drug regimens and biologics predicted an increased and decreased rate of hospitalization, respectively, with the latter driven by TNFα inhibitors. Limitations A single-center study somewhat limits generalization to community-based settings. Only patients tested for COVID-19 were analyzed. Conclusion IS therapies for IMIDs are not associated with a significantly greater risk of SARS-CoV-2 or severe sequelae when controlling for other factors, and TNFα inhibitors may decrease odds of severe infection.

The COVID-19 pandemic has sparked uncertainty throughout society and the medical 60 community on how to best quell the spread of the virus, allocate critical resources, and care for 61 high-risk populations, especially as new cases surge. 1-4 Concerns about potential increased risk 62 for patients receiving immunosuppressive (IS) treatment for immune-mediated inflammatory 63 disease (IMID) are warranted. Several professional societies suggest that clinicians should 64 discontinue or reduce the use of IS agents in patients that test positive for SARS-CoV-2, 1,5,6 65 though there is insufficient evidence to recommend discontinuation of IS therapy in others. 66

has not been reported as a risk factor in previous coronavirus outbreaks, and did not appear as 68 a frequent comorbidity in studies of the initial outbreak of SARS-CoV-2 in China. 7 Furthermore, the effect of perturbing a pro-inflammatory state in an already dysregulated 75 immune system during a disease flare might provoke a cytokine storm in patients with mild or 76 asymptomatic COVID-19, as has been seen in cancer patients who contract COVID-19 soon 77 after receiving immunotherapy. 12 Targeted immunomodulation may even prove beneficial, 78 evidenced by data from previous coronaviruses and ongoing clinical trials. [13] [14] [15] Given this 79 uncertainty, there is a great need for more data concerning patient outcomes in the early stages 80 of the outbreak to guide clinical decision-making. 81

During the COVID-19 pandemic Detroit has had a high incidence of cases, and is thus an 82 excellent population from which to draw a single-center study, reducing the possible effect of confounding environmental factors. From February 1 st to April 18 th , 2020, the Henry Ford Health 84 System (HFHS) in Detroit, MI tested a total of 15,345 individuals for SARS-CoV-2 using PCR, of 85 which 5,881 (38.3%) were positive. Of positive cases, 2,650 (45.1%) were admitted, 522 (8.9%) 86 required a ventilator, and 322 (5.5%) died ( Figure S1 ). 87 88 Methods 89

We performed a retrospective cohort study ( Figure 1 ) utilizing a chart review of patients tested 91

for SARS-CoV-2 with laboratory polymerase chain reaction (PCR) at Henry Ford Health System 92 (HFHS) between February 1 st and April 18 th , 2020 that were being treated with IS drugs 93 commonly utilized in dermatological treatment and IMID patients (Table S1) omalizumab, belimumab, rituximab); no patients treated with IL-1 or IL-6 inhibitors were 101 identified. For inclusion, patients were required to be treated with IS medication at least 1 month 102 prior to testing, which was validated through review of the treating physician notes and patient 103 communications without relying on auto-populated medication lists. Systemic corticosteroid use 104 was not used as an independent identifying medication to avoid capturing patients on short-term 105 corticosteroid regimens, however some IMID patients were concurrently treated with long-term 106 corticosteroid regimens of at least 2 months in conjunction with another IS medication and were 107 noted as such. Any patients receiving chemotherapy or those whose IS medication could not be 108 verified as current were excluded. IMID status was verified via review of physician notes, and 109 those taking IS medications for non-IMID indications, such as for the prevention of transplant 110 rejection, were not included. Two-hundred thirteen IMID patients treated with IS therapeutics 111

were included and will be referred to as the IMID cohort (Table 1) . Individuals tested at HFHS 112 during this time were under high suspicion for COVID-19, which included symptomatic patients 113 or those with a known exposure presenting to the emergency department for testing, patients 114 admitted, and HFHS healthcare providers seeking testing over concern of potential exposure. 115

Asymptomatic patients without a verified exposure were not tested during this time. Policy for 116 testing, admission, or ventilation did not vary based on comorbidities, demographics, or 117 immunosuppressive treatments during this time. For patients tested multiple times, any positive 118 result was considered a COVID-19 positive case. All research activities were conducted with 119 approval of the Henry Ford Health System institutional review board (#13768). We tracked 120 outcomes for each patient via review of physician notes. 121

The outcomes of interest were COVID-19 status (positive or negative) via PCR test, admission 123 status (admitted or not admitted), ventilatory status (requiring or not requiring invasive 124 mechanical ventilation), and vital status (living or deceased). We used two-group comparisons 125 to assess the overall outcomes for the IMID cohort against the general population tested at 126 HFHS. For the purposes of this comparison, admission status, ventilator status, and mortality 127 data were used only for those who tested positive for COVID-19. We then categorized IS 128 medications into two primary groups -biologics and disease-modifying anti-rheumatic drugs 129 (DMARDs), with hydroxychloroquine classified as an independent non-IS medication given its 130 potential use in both IMID and COVID-19. We sub-categorized our cohort into those with conditions, hidradenitis suppurativa, myasthenia gravis, sarcoidosis, urticaria, and uveitis (Table  136 1). We performed two-group comparisons to assess the odds ratio of outcomes of interest as a 137 function of IMID type or IS therapy present (Table 2) , with admission status, ventilator status, 138 and mortality again being used only for those who tested positive for COVID-19. We additionally 139 assessed admission status as a function of IS therapy class among the IMID cohort as a whole 140 to determine if effects on admission rates were affected by COVID-19 status (Table S2 ). These 141 comparisons were performed using chi-square testing, with Fisher's exact test used when 142 expected counts were <5. Further investigation was performed using multivariate logistic 143 regression models while controlling for age, race, gender, COVID-19 status, IS medication, and 144 comorbidities as documented in physician notes, including cardiac, pulmonary, renal, 145 gastrointestinal, endocrine, and history of cancer (Table S3) subsequently discharged, 6 died, and 4 remained admitted and continued to receive care. 155

Among 136 IMID patients who tested negative for SARS-CoV-2, 29 (21.3% of negative cases) 156

were admitted for continued suspicion of COVID-19 or reasons unrelated to COVID-19 and 2 (1.5% of negative cases) required a ventilator; any subsequent COVID-19 testing was also 158 negative. Twenty-five of these admitted patients were discharged and 4 died of non-COVID-19-159 related reasons. Relevant additional information can be found in Table S4 (Table S5) . 164

While not corrected for additional variables, the following results from two-group comparison 165 within the study cohort bear noting. Use of systemic corticosteroids as compared to non-use 166 significantly increased the odds of admission within the cohort generally as well as among those 167 who tested positive for COVID-19 (OR 5.48, CI 1.3 to 26) ( Table 2) . Receiving DMARD as 168 compared to non-DMARD therapy and multidrug therapy as compared to monotherapy each led 169 to increased odds of admission within the cohort generally, though this was not true when 170 analysis was restricted to only those who tested positive for COVID-19 (Table 2) . Multidrug 171 therapy as compared to monotherapy also gave greater odds of a positive COVID-19 test within 172 the cohort (OR 2.3, CI 1.1 to 4.8) (Table S2 ); no single medication among multidrug patients 173 accounted for this result. Use of biologics as compared to non-biologic therapy was associated 174 with lower odds of admission among IMID patients generally as well as among those who tested 175 positive (OR 0.33, CI 0.14 to 0.82) (Table S2) . No IMID type was associated with a particular 176 outcome (Table 2 and S2) . 177

When logistic regression was performed within the cohort to correct for contributing variables, 178 significant positive predictors of admission status included age >65, SARS-CoV-2 status, 179 multidrug therapy, and presence of a pulmonary comorbidity, while biologic therapy proved to 180 be a negative predictor of admission (OR 0.26, CI 0.066 to 0.95) (Figure 2a) . In turn, race was 181 the only factor that proved able to predict COVID-19 status, with African Americans (OR 3.0, CI 1.6 to 5.7) having greater odds of a positive test (Table S6a) . However, neither race or any 183 other factor besides age >65 was a significant predictor of mortality (OR 13, 2.5 to 120) for IMID 184 patients as a whole (Table S6b) . When patients receiving monotherapy were compared to one 185 another to remove the confounding effects of additional IS medications, patients treated with 186

TNFα inhibitor monotherapy had significantly lower odds of admission (OR 0.16, CI 0.032 to 187 0.72) (Figure 2b ). There were no other significant effects on outcomes of interest due to IS 188 medications after multivariate analysis. In recently published cohorts of IMID patients with COVID-19, those who were hospitalized as 207 opposed to being treated on an outpatient basis tended to be older, had a greater number of 208 comorbidities, and were more likely to use systemic corticosteroids, hydroxychloroquine, or 209 methotrexate. 16, 20 In our study, corticosteroids and multi-drug therapy appeared on paired 210 analysis to increase the odds of hospitalization among IMID patients who were infected, but only 211 multi-drug therapy proved predictive of disease course when controlling for other contributing 212 variables. A possible explanation for this seeming discrepancy is our accounting for a greater 213 variety of contributing comorbidities than either prior study, including several thought to affect 214 the course of COVID-19, such as kidney impairment, 21,22 chronic liver disease, 23,24 history of 215 malignancy, 25,26 and preexisting pulmonary compromise beyond chronic obstructive pulmonary 216 disease. Each of these was present within our dataset, and we have no reason to believe they 217 would not be present among similar patient populations as well. Once these variables were 218 accounted for, any negative contribution of individual classes of IS medications to the course of 219 COVID-19 disappeared. As significant comorbid conditions were grouped by organ system, we 220 were unable to infer conclusions about any single comorbid disease. 221

While multi-drug therapy did portend a higher risk of hospitalization as compared to 222 monotherapies, this result could be due to either additive immunosuppression or a greater 223 burden of disease and overall lower functional status among patients on such combination 224 regimens. However, the result remains instructive for dermatologists, who may want to consider 225 abridging therapeutic regimens to monotherapy whenever possible or advising patients whose 226 care necessitates multi-drug regimens about their higher risk for hospitalization. 227

No other therapeutic or IMID condition showed an effect on outcomes from COVID-19 among 228 those treated for IMIDs, including those with potentially more severe preexisting pulmonary 229 compromise, such as patients with connective tissue disease. This finding mirrors other recently 230 published data 16 and suggests that those being treated in dermatology clinics for IMID 231 conditions should not be considered high-risk for COVID-19 based upon that IMID condition 232

Several reports have suggested that IS therapy does not increase the prevalence of COVID-19 234 in patients with IMID. 27,28 However, these studies had the potential to miss many COVID-19 235 cases, as they surveyed IMID patients for any history of a diagnosis, regardless of testing, and 236

were unable to account for asymptomatic carriers or sheltering among IMID patients. By 237 restricting our study only to patients suspected and tested for SARS-CoV-2, we excluded 238 asymptomatic or sheltered individuals entirely and gained a cohort of both positive and negative 239 patients, from which we are able to conclude that no IS therapy increased the odds of testing with African Americans at greater odds of testing positive (Table S6a ). This association was 245 likely in part due to the epidemiology of SARS-CoV-2 in Detroit, which is roughly 78% African 246

American and has had the greatest density of COVID-19 cases in Michigan, 29 though further 247 expansion is beyond the scope of this article. 248

Performing a single-center retrospective chart review limits the total number of patients in our 249 study as well as the number of patients using any given therapeutic, which somewhat limits the 250 generalizability to community-based settings, yet also removes confounding variables such as 251 the differences between hospital systems and environmental exposures that could affect 252 disease course and outcome in larger databases involving multiple hospitals. The fact that 253 HFHS is located in a SARS-CoV-2 hotspot allowed us to collect a substantial cohort of patients 254 nonetheless and perform analysis from which to inform clinical care. Based on the available 255 data from our study and others, there appears to be no need to discontinue usage of particular IS medications in attempt to reduce risk of COVID-19 and related illness, though consideration 257 should be given to reducing multi-drug regimens to monotherapy wherever possible. 258

Furthermore, TNFα inhibitors may reduce the risk of more severe disease among IMID patients 259 requiring IS therapy. 

American Academy of Dermatology. Guidance on the use of biologic agents during

Should biologics for psoriasis be interrupted in 268 the era of COVID-19?

Rheumatologists rapidly adjust patient care during COVID-19 pandemic

COVID-19: A global transplant perspective on 272 successfully navigating a pandemic

COVID-19 Clinical Guidance for Adult Patients with 276

Clinical-Guidance-Summary-Patients-with-Rheumatic-Diseases

Coronaviruses and immunosuppressed patients. The facts during the third 280 epidemic

Comorbidity and its impact on 1590 patients with 282 COVID-19 in China: A Nationwide Analysis

Novel Coronavirus Disease (COVID-285 19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling

):e173. 291 11. Bashyam AM, Feldman SR. Should patients stop their biologic treatment during the 292 COVID-19 pandemic

Patients with Cancer Appear More Vulnerable to SARS-295

CoV-2: A Multi-Center Study During the COVID-19 Outbreak

Inhibition of tumor necrosis factor reduces the 298 severity of virus-specific lung immunopathology

Ongoing Clinical Trials for the Management of the COVID-19

COVID-19: risk for cytokine targeting in chronic 303 inflammatory diseases?

Characteristics associated with 305 hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19

Global Rheumatology Alliance physician-reported registry

Trials of anti-tumour necrosis factor therapy for 309

COVID-19 are urgently needed. The Lancet

COVID-19: a case for inhibiting IL-17?

* The odds ratios and 95% confidence intervals drawn from two groups comparison have not been 380 adjusted and should not be used to infer definitive effects. DMARD denotes disease-modifying anti-381 rheumatic drug, IMID immune-mediated inflammatory disease, RA rheumatoid arthritis, PsA psoriatic 382 arthritis, SLE systemic lupus erythematosus, DM dermatomyositis, PM polymyositis, MCTD mixed 383 connective tissue disease, ILD interstitial lung disease, Scl scleroderma and systemic sclerosis

§ COVID-19 positivity among all IMID patients

Little is known about the impact of systemic immunosuppressive (IS) medications common to dermatology on COVID-19 risk

• IS for IMID were not associated with increased risk of SARS-CoV-2 infection or severe sequelae, and anti-TNFα monotherapy was associated with decreased admission rate